{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:34Z","timestamp":1753892074345,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31371509"],"award-info":[{"award-number":["31371509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the effect of different single and combined pre-admission antihypertensive drug regimens on the prognosis of critically ill patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective cohort study using data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. All initial ICU admission records of patients with hypertension and previous antihypertensive exposure before ICU admission were included. Our primary outcome was 90-day mortality. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to balance the distribution of baseline characteristics. Logistic regression analysis and subgroup analysis were performed to determine the independent effect of different single and combined antihypertensive drug regimens on 90-day mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13,142 patients were included in the final analysis. The 90-day mortality rate in the combined groups is lower than that in the single therapy group (10.94% vs 11.12%), but no statistical significance was found in the original cohort (<jats:italic>p<\/jats:italic> = 0.742). After adjustment for potential confounders, the significantly decreased 90-day mortality rate was found in the combined groups (10.78% vs 12.65%, <jats:italic>p<\/jats:italic> = 0.004 in PSM; 10.34% vs 11.90%, <jats:italic>p<\/jats:italic> = 0.007). Patients who were exposed to either ACEIs or ARBs had a better prognosis than those not exposed (7.19% vs 17.08%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001 in single antihypertensive groups; 8.14% vs18.91%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001 in combined antihypertensive groups). The results keep robustness in the PSM and IPTW cohorts. In the logistic regression model analysis, combined therapy was associated with a 12%\u201320% reduced risk of 90-day death after adjusting potential confounders (OR 0.80\u20130.88, all <jats:italic>p<\/jats:italic> &amp;lt; 0.05), while exposure to ACEIs or ARBs was associated with the decreased risk of 90-day death by 52%\u201362% (OR 0.38\u20130.48, all <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and 40%\u201362% (OR 0.38\u20130.60, all <jats:italic>p<\/jats:italic> &amp;lt; 0.001) in the single and combined therapy groups, respectively. The results were still robust to subgroup analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pre-admission combined antihypertensive therapy is associated with a significantly lower risk of death than exposure to single antihypertensives in critically ill patients. Meanwhile, either ACEIs or ARBs seem to be the optimal candidates for both single and combined therapy. Further high-quality trials are needed to confirm our findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1385397","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:31:38Z","timestamp":1724819498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of different single and combined antihypertensive drug regimens on the mortality of critical care patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Yipeng","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","article-title":"Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study","volume":"175","author":"Benetos","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e33881","DOI":"10.1097\/MD.0000000000033881","article-title":"Predictive value of risk factors for prognosis of patients with sepsis in intensive care unit","volume":"102","author":"Chen","year":"2023","journal-title":"Med. Baltim."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e017297","DOI":"10.1161\/JAHA.120.017297","article-title":"Renin-angiotensin system blockers and adverse outcomes of influenza and pneumonia: a Danish cohort study","volume":"9","author":"Christiansen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study","volume":"30","author":"Chrysant","year":"2008","journal-title":"Clin. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11906-012-0280-9","article-title":"Should two-drug initial therapy for hypertension be recommended for all patients","volume":"14","author":"Cowart","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0266038","DOI":"10.1371\/journal.pone.0266038","article-title":"Long-term outcomes of hospital survivors following an ICU stay: a multi-centre retrospective cohort study","volume":"17","author":"Doherty","year":"2022","journal-title":"PLoS ONE"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/eurheartj\/ehz381","article-title":"The 2018 ESC\/ESH Guidelines for the management of arterial hypertension: a German point of view","volume":"40","author":"Emrich","year":"2019","journal-title":"Eur. Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/phar.2677","article-title":"A propensity score-matching analysis of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker exposure on in-hospital mortality in patients with acute respiratory failure","volume":"42","author":"Fang","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13054-021-03725-z","article-title":"Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study","volume":"25","author":"Flannery","year":"2021","journal-title":"Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.3390\/jcm11216486","article-title":"The impact of different antihypertensive drugs on cardiovascular risk in isolated systolic hypertension with type 2 diabetes patients","volume":"11","author":"Gao","year":"2022","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7547-10-14","article-title":"Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines","volume":"10","author":"Geroy","year":"2012","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"key":"B15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajem.2022.10.006","article-title":"Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis","volume":"62","author":"Hasegawa","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4331\/wjbc.v6.i3.209","article-title":"Inflammation, oxidative stress and renin angiotensin system in atherosclerosis","volume":"6","author":"Husain","year":"2015","journal-title":"World J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e044010","DOI":"10.1136\/bmjopen-2020-044010","article-title":"Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study","volume":"11","author":"Jeffery","year":"2021","journal-title":"BMJ Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e060305","DOI":"10.1136\/bmjopen-2021-060305","article-title":"Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study","volume":"12","author":"Jeffery","year":"2022","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/jhh.2009.22","article-title":"Profiles of mortality among Chinese hypertensive patients in Hong Kong: a cohort study","volume":"23","author":"Jiang","year":"2009","journal-title":"J. Hum. Hypertens."},{"volume-title":"MIMIC-IV","year":"2021","author":"Johnson","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11795468221095875","DOI":"10.1177\/11795468221095875","article-title":"Early diuretics for de-resuscitation in septic patients with left ventricular dysfunction","volume":"16","author":"Jones","year":"2022","journal-title":"Clin. Med. Insights Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"619524","DOI":"10.3389\/fphar.2021.619524","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on angiotensin-converting enzyme 2 levels: a comprehensive analysis based on animal studies","volume":"12","author":"Kriszta","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.intimp.2009.04.010","article-title":"Amlodipine inhibits TNF-alpha production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K\/Akt pathway","volume":"9","author":"Li","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1097\/CCM.0b013e31825b9509","article-title":"Previous prescription of \u03b2-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis","volume":"40","author":"Macchia","year":"2012","journal-title":"Crit. care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"R198","DOI":"10.1186\/cc9317","article-title":"Effect of oral \u03b2-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study","volume":"14","author":"Noveanu","year":"2010","journal-title":"Crit. Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e022870","DOI":"10.1161\/JAHA.121.022870","article-title":"Effects of renin-angiotensin-aldosterone system inhibitors on long-term major adverse cardiovascular events in sepsis survivors","volume":"10","author":"Ou","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/biomedicines11071974","article-title":"Calcium Channel blockers and the risk of exacerbation in patients with chronic obstructive pulmonary disease: a nationwide study of 48,488 outpatients","volume":"11","author":"Rastoder","year":"2023","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1517\/14728220903460332","article-title":"Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach","volume":"14","author":"Salgado","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"B31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijcard.2008.11.104","article-title":"ACE-inhibitor therapy and survival among patients with multiorgan dysfunction syndrome (MODS) of cardiac and non-cardiac origin","volume":"140","author":"Schmidt","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thromb. Haemost."},{"key":"B33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.amjsurg.2017.06.007","article-title":"Outpatient beta-blockers and survival from sepsis: results from a national cohort of Medicare beneficiaries","volume":"214","author":"Singer","year":"2017","journal-title":"Am. J. Surg."},{"key":"B34","first-page":"341","article-title":"Managing hypertension using combination therapy","volume":"101","author":"Smith","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"B35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0140-6736(99)07330-4","article-title":"Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials","volume":"355","author":"Staessen","year":"2000","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/CCM.0000000000002236","article-title":"Prior use of calcium channel blockers is associated with decreased mortality in critically ill patients with sepsis: a prospective observational study","volume":"45","author":"Wiewel","year":"2017","journal-title":"Crit. care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1003442","DOI":"10.3389\/fcvm.2022.1003442","article-title":"Early ACEI\/ARB use and in-hospital outcomes of acute myocardial infarction patients with systolic blood pressure <100 mmHg and undergoing percutaneous coronary intervention: findings from the CCC-ACS project","volume":"9","author":"Zhao","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/MJT.0000000000000312","article-title":"Preadmission use of calcium channel blockers and outcomes after hospitalization with pneumonia: a retrospective propensity-matched cohort study","volume":"24","author":"Zheng","year":"2017","journal-title":"Am. J. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"918385","DOI":"10.3389\/fphar.2022.918385","article-title":"The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: an observational study using the MIMIC database","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:31:42Z","timestamp":1724819502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":40,"alternative-id":["10.3389\/fphar.2024.1385397"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1385397","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"article-number":"1385397"}}